cas 123536-15-2|| where to buy 1-Azabicyclo[2.2.2]octan-3-amine, (3R)-

Nom du produit:1-Azabicyclo[2.2.2]octan-3-amine, (3R)-

IUPAC Name:(3R)-1-azabicyclo[2.2.2]octan-3-amine

Unité d'emballage	Stock disponible	Prix($)
CM431540-100mg	in stock	ƤǕ
CM431540-250mg	in stock	ȦǆǕ
CM431540-1g	in stock	ſȷɐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 123536-15-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:123536-15-2; Formule moléculaire:C7H14N2; Point de fusion:-; Code SMILES:N[C@H]1CN2CCC1CC2; Densité:

: Numéro de catalogue:CM431540; Poids moléculaire:126.2; Point d'ébullition:; N° Mdl:MFCD08669630; Stockage:

: Quinuclidines; Quinuclidine is an organic compound with the formula HC(C2H4)3N. It is a bicyclic amine that can be viewed as a tied-back version of triethylamine. It is a colorless solid. It is used as a reagent (base) and catalyst. It can be prepared by the reduction of quinuclidine. It finds various applications in the field of organic synthesis and pharmaceutical research. Quinuclidine derivatives are used as catalysts, chiral building blocks, and intermediates in the synthesis of pharmaceutical compounds. Additionally, it has been investigated for its potential pharmacological properties, including its role as a neurotransmitter modulator.; Quinuclidine | C7H13N | CID 7527 - Chemenu; Quinuclidine | C7H13N | CID 7527; Discover Quinuclidine (C7H13N) at Chemenu. Find information about its chemical properties, applications, and CID 7527. Explore our wide selection of high-quality Quinuclidine compounds for your research and industrial needs.

: SENS-401; Sensorion announced it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation. SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss (SSNHL). It is aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.